T6704

Tandospirone

≥98% (HPLC)

• 同義詞: (1R*,2S*,3R*,4S*)-N-(4-(4-(2-Pyrimidinyl)-1-piperazinyl)butyl)-2,3-norbornanedicarboximide citrate salt, SM 3997
• 經驗公式（希爾表示法）: C₂₁H₂₉N₅O₂
• CAS號碼: 87760-53-0
• 分子量：: 383.49
• 分類程式碼代碼: 51111800
• PubChem物質ID: 329826853
• NACRES: NA.77

屬性

• 化驗: ≥98% (HPLC)
• 儲存條件: protect from light
• 溶解度: DMSO: 38 mg/mL
• 起源: Dainippon Sumitomo
• 儲存溫度: 2-8°C
• SMILES 字串: O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1CCCCN4CCN(CC4)c5ncccn5
• InChI: 1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-18H,1-2,4-5,8-14H2/t15-,16+,17+,18-
• InChI 密鑰: CEIJFEGBUDEYSX-FZDBZEDMSA-N

描述

生化／生理作用

Tandospirone is a partial agonist at 5HT_1A receptors. It significantly reduces haloperidol-induced bradykinesia in a dose-dependent manner. The potency of tandospirone is equal to that of buspirone and approximate half that of diazepam. The potency of tandospirone as a dopamine antagonistic is less than 1/4 that of buspirone.

特點和優勢

This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全資訊

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H315,H319,H335
• 防範說明: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• 危險分類: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• 標靶器官: Respiratory system
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable